Trial Profile
INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms INNOVADOR; INNOVATION
- 02 Feb 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
- 06 Jun 2023 Primary endpoint (The primary endpoint of the phase II study is the major pathological response rate ( 10% vital tumor cells).) has not been met according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 After publication of the FLOT-4 study, the protocol was amended. CT changed to four cycles FLOT (Al-Batran Lancet 2019) with FOLFOX or CAPOX as alternative for pts ineligible for FLOT.In the experimental arms, T and P were continued beyond CT at the same dose for a total of 17 cycles.